NUGC-4 Cells
USUSD$800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | NUGC-4 is a human gastric cancer cell line established from metastatic paragastric lymph nodes of an adult patient with poorly differentiated adenocarcinoma exhibiting focal signet-ring cell carcinoma features. The cell line was developed from tumor tissues acquired during surgical resection and has been successfully maintained both in vitro and as a transplantable tumor in nude mice. In vitro, NUGC-4 cells grow predominantly as spherical cells, with some free-floating populations, and exhibit epithelial characteristics confirmed via electron microscopy. These include well-developed endoplasmic reticulum, Golgi apparatus, cytoplasmic filaments, and desmosome-like junctions. Notably, cells contain intracytoplasmic microcysts, contributing to their unique morphology. Chromosomal analysis reveals that NUGC-4 cells possess a near-triploid karyotype with a modal chromosome number ranging from 52 to 54 in vitro and approximately 53 in vivo. The cells display consistent trisomies across several chromosomal groups, though no specific marker chromosomes were identified. Doubling time for NUGC-4 is approximately 29.9 hours, indicating a moderately rapid proliferation rate under standard culture conditions. Among three related gastric cancer lines (NUGC-2, NUGC-3, and NUGC-4), NUGC-4 exhibited the highest in vitro sensitivity to anticancer agents such as mitomycin C and adriamycin, suggesting a heightened responsiveness to certain DNA-damaging chemotherapeutics. Histologically, xenografts derived from NUGC-4 resemble the parent tumor, maintaining features of a scirrhous carcinoma pattern. The line has been used in drug response profiling and molecular characterization studies as part of large-scale cancer cell line projects. Its combination of clinical origin, histological fidelity, and drug sensitivity profile makes NUGC-4 a relevant model for studying aggressive and chemoresponsive gastric adenocarcinomas with diffuse-type characteristics. |
|---|---|
| 生物體 | Human |
| 組織 | Metastatic |
| 疾病 | Gastric signet ring cell adenocarcinoma |
| 轉移部位 | Paragastric lymph node |
| 同義詞 | NUGC4, NU-GC-4, Nagoya University-Gastric Cancer-4 |
特徵
| 年齡 | 35 years |
|---|---|
| 性別 | Female |
| 族裔 | Japanese |
| 生長特性 | Adherent |
監管數據
| 引用 | NUGC-4 (Cytion catalog number 305645) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 9606 |
| Cellosaurus 編號 | CVCL_3082 |
生物分子資料
處理方式
| 培養基 | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| 營養補充品 | Supplement the medium with 10% FBS |
| 解離試劑 | Acccutase |
| 倍增時間 | 29.9 hours |
| 播種密度 | 1 to 4 x 104 cells/cm2 |
| 流體更新 | 2 to 3 times per week |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
| 不孕症 | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
| 轉移部位: | Lymph node |
|---|
分析證明書 (CoA)
| 批次編號 | 證書類型 | 日期 | 型號 |
|---|---|---|---|
| 305645-090326 | 分析證明書 | 31. Mar. 2026 | 305645 |